Effect tDCS of Motor Cortex on Chemotherapy Induced Peripheral Neuropathy

Assiut University26 enrolled

Overview

Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin) . CIPN is one of several long term side effects of anticancer medications that can appear during and after treatment. CIPN symptoms include pain, dysesthesia, motor and sensory disorders. CIPN can also be insufficiently responsive to pharmaceutical therapy similar to other types of refractory neuropathic pain This study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation (CE-tDCS) over the primary motor cortex (M) in management of chemotherapy induced peripheral neuropathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

transcranial dirrect current brain stimuationDEVICE

tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * any stage of cancer, with a confirmed treatment plan consisting of taxane-based or oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy with VAS score ≥ 3 that are resistant to medical treatment Exclusion Criteria: * patients with intracranial metallic devices or with pacemakers or any other device. - -W those with extensive myocardial ischemia, * higher brain dysfunction, * migraine headache, * brain cancer or metastasis and * those known to have epilepsy

Locations (1)

South Egypt Cancer Institute

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

changes in the visual analogue scale

patient describe his pain scored from 0 to 10 where 0=no pain and 10=the worst pain imaginable

Time frame: 0 (prestimulation), on the 5th day, 15th days and one month after the last session

Secondary Outcomes

changes in the Leeds Assessment of neuropathic Symptoms and signs (LANSS)

the patients will be asked to describe his pain by answering questions in yes or no; score ≥ 12 suggests neuropathic pain is likely to be involved and score \< 12 suggests that neuropathic pain is unlikely to be involved

Time frame: 0 (prestimulation),on the 5th day, 15th days and one month after the last session

Central Contacts

Shereen M Kamal, Associate professor

CONTACT

01006279209 sheridouh79@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.